On July 24, 2017, Paradigm Diagnostics announced a major price reduction of PCDx. “The efficiency of our proprietary process and transition to an optimized platform enables us to share the savings with our patients, customers, research partners, and distributors without impacting our industry leading accuracy, speed, and comprehensiveness,” said David Mallery, CEO.
“A combination of IHC, mRNA, and sensitive DNA sequencing enables PCDx to identify additional potential druggable targets that most other approaches aren’t even looking for,” said Dr. Glen Weiss, Medical Oncologist and a Clinical Oncology Advisor to Paradigm.
PCDx currently hits 86 unique FDA approved therapies and 13 combination therapies and their mRNA expression component alone covers an additional twenty (23) FDA approved agents on compendium with proven clinical utility in most major cancer types that are often overlooked by not utilizing this methodology.
“We strive to provide the most comprehensive, accurate, and fastest solution while also at the lowest cost,” said David Mallery, CEO. “By sharing our savings we are able to further expand our collaborations with oncology practices, academic medical centers, distributors, international customers, and research innovators to help deliver the best treatment recommendations for patients.”
Paradigm Diagnostics offers accurate, comprehensive and clinically actionable cancer genomic profiling and therapeutic information in 4-5 business days to better support patient care. The Paradigm Cancer Diagnostic (PCDx®) comprehensive genomic profiling test analyzes DNA, RNA, and Fusions as well as Protein by immunohistochemisty to provide treating physicians and patients with more precise information about the specific cancer pathways in the tumor to allow for more effective decision-making.